Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial
Posted:
In 2022, about 330,000 people around the world were diagnosed with the skin cancer melanoma, with about 60,000 people dying from the condition.
On August 19, pharmaceutical companies Merck and Moderna announced the phase 3 clinical study results for an experimental therapy designed to help lower the recurrence rate in people with stage IIB-IV melanoma who have had their tumor completely removed.
GIANT Health is delighted to welcome the NHS Innovation Accelerator (NIA) as a valued partner for GIANT Health 2026, where they will bring together a dedicated NIA Pavilion showcasing a selection of pioneering innovations helping to transform health and care…
GIANT Health Event 2026 is pleased to welcome MediWales as a media partner, strengthening connections between the global health technology community and Wales’ thriving life science ecosystem.
MediWales is the independent, not-for-profit life science network for Wales, bringing together organisations…
Attendees
Sponsors and Exhibitors
Contact us